$IDYA: IDEAYA Biosciences, Inc. - Common Stock

IDEAYA Biosciences, Inc. (IDYA) is a clinical-stage biotechnology company focused on developing and commercializing novel immunotherapy products for the treatment of cancer. The company's lead product candidate, ide-001, is a first-in-class dendritic cell-based immunotherapy that is currently in Phase 2 clinical trials for the treatment of metastatic colorectal cancer (mCRC). IDEYA is also developing ide-002, a second-generation dendritic cell-based immunotherapy that is currently in preclinical development for the treatment of multiple cancer indications.

IDEYA was founded in 2013 by a team of experienced scientists and entrepreneurs with a deep understanding of the immune system and cancer immunotherapy. The company is headquartered in Cambridge, Massachusetts, and has a research and development facility in San Diego, California.

IDEYA's technology platform is based on the company's proprietary dendritic cell (DC) technology. DCs are immune cells that play a critical role in the body's immune response to cancer. IDEYA's DCs are engineered to express tumor-specific antigens, which allows them to activate the immune system to target and kill cancer cells.

ide-001 is a first-in-class DC-based immunotherapy that is currently in Phase 2 clinical trials for the treatment of mCRC. mCRC is a particularly aggressive form of cancer with a high unmet need for new treatment options. ide-001 has shown promising results in early clinical trials, and IDEYA is currently evaluating the drug in a Phase 2 trial in patients with mCRC that has progressed after standard therapy.

ide-002 is a second-generation DC-based immunotherapy that is currently in preclinical development for the treatment of multiple cancer indications. ide-002 is designed to be more potent and durable than ide-001, and it is expected to have a wider range of applications. IDEYA plans to initiate clinical trials of ide-002 in 2023.

In addition to its lead product candidates, IDEYA is also developing a pipeline of other DC-based immunotherapy products. The company is also developing a proprietary technology platform for the manufacturing of DCs, which it plans to license to other companies.

IDEYA is well-positioned to be a leader in the field of cancer immunotherapy. The company has a strong technology platform, a promising clinical pipeline, and a experienced management team. IDEYA is poised to make significant progress in the development of new cancer immunotherapy products in the years to come.

Here are some additional details about IDEYA Biosciences:

• The company was founded in 2013 by a team of experienced scientists and entrepreneurs with a deep understanding of the immune system and cancer immunotherapy.
• IDEYA's lead product candidate, ide-001, is a first-in-class dendritic cell-based immunotherapy that is currently in Phase 2 clinical trials for the treatment of metastatic colorectal cancer (mCRC).
• IDEYA is also developing ide-002, a second-generation dendritic cell-based immunotherapy that is currently in preclinical development for the treatment of multiple cancer indications.
• IDEYA is headquartered in Cambridge, Massachusetts, and has a research and development facility in San Diego, California.
• IDEYA is backed by a strong financial team, including investors such as Flagship Pioneering, Versant Ventures, and Polaris Partners.
• IDEYA is well-positioned to be a leader in the field of cancer immunotherapy. The company has a strong technology platform, a promising clinical pipeline, and a experienced management team. IDEYA is poised to make significant progress in the development of new cancer immunotherapy products in the years to come.